| 2025-11-14 |
详情>>
股本变动：
变动后总股本2054.83万股
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.23美元,归母净利润-3501.5万美元,同比去年增长-40.69%
|
| 2025-08-29 |
详情>>
业绩披露：
2025年中报每股收益-1.56美元,归母净利润-2412.5万美元,同比去年增长-46.27%
|
| 2025-05-16 |
详情>>
业绩披露：
2025年一季报每股收益-0.69美元,归母净利润-1075万美元,同比去年增长-12.83%
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-2.56美元,归母净利润-3925.8万美元,同比去年增长-45.62%
|
| 2025-03-31 |
详情>>
业绩披露：
2022年年报每股收益-3.01美元,归母净利润-4101.4万美元,同比去年增长-11.9%
|
| 2024-11-15 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.77美元,归母净利润-2488.8万美元,同比去年增长-19.18%
|
| 2024-08-17 |
详情>>
业绩披露：
2024年中报每股收益-1.23美元,归母净利润-1649.3万美元,同比去年增长-1.51%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.71美元,归母净利润-952.8万美元,同比去年增长-58.56%
|
| 2024-04-01 |
财报披露：
美东时间 2024-04-01 盘前发布财报
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-2.02美元,归母净利润-2696万美元,同比去年增长34.27%
|
| 2024-03-06 |
复牌提示：
2024-03-05 15:38:29 停牌，复牌日期 2024-03-05 15:48:29
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.56美元,归母净利润-2088.3万美元,同比去年增长2.77%
|
| 2023-02-14 |
股东大会：
将于2023-03-20召开股东大会
会议内容 ▼▲
- 1.To approve and adopt the agreement and plan of merger (the “Merger Agreement”) by and between the Company and CASI Pharmaceuticals Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands and a wholly-owned subsidiary of the Company (“CASI Cayman”), which includes a plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form as attached as Annex A to the Merger Agreement (the “Plan of Merger”), pursuant to which the Company will merge with and into CASI Cayman, with CASI Cayman as the surviving company upon the merger becoming effective, and whereby each issued and outstanding share of the common stock of the Company will be converted into the right to receive one ordinary share, par value US$0.0001 each, of CASI Cayman, credited as fully paid (the “Redomicile Merger”).
2.To consider and vote on any proposal to adjourn the Special Meeting, from time to time, to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement and the Redomicile Merger at the time of the Special Meeting;
3.To transact any other business that may properly come before the Special Meeting.
|
| 2022-06-13 |
详情>>
内部人交易：
He Wei-Wu共交易3笔
|
| 2022-05-26 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2022-04-15 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect two directors;
2.To ratify the appointment of KPMG Huazhen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve the proposal to authorize our Board of Directors, in its discretion but no later than the one-year anniversary of the 2022 annual meeting of stockholders (the “Annual Meeting”), to amend our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock and treasury shares, at a ratio in the range of 1-for-2 to 1-for-20, such ratio to be determined by the board of directors and included in a public announcement (the “Reverse Stock Split Proposal”);
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-10 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.To elect two directors;
2.To ratify the appointment of KPMG Huazhen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve the Company’s 2021 Long-Term Incentive Plan;
4.To approve the issuance of equity compensation to the Company’s Chairman and Chief Executive Officer pursuant to Nasdaq Listing Rule 5635(c) and, if applicable, Nasdaq Listing Rule 5635(b);
5.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2020-04-22 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- 1.To elect two directors;
2.To ratify the appointment of KPMG Huazhen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve an advisory resolution on executive compensation;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-20召开股东大会
会议内容 ▼▲
- 1.To elect two directors;
2.To approve an amendment to our 2011 Long-Term Incentive Plan increasing the number of shares of Common Stock reserved for issuance from 20,230,000 to 25,230,000;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 170,000,000 to 250,000,000;
4.To approve the issuance of equity compensation to the Chairman and CEO pursuant to Nasdaq Listing Rule Section 5635(c) and, if applicable, Nasdaq Listing Rule Section 5635(b);
5.To ratify the appointment of KPMG Huazhen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
6.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2018-04-17 |
股东大会：
将于2018-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three directors;
2.To approve amendments to our 2011 Long-Term Incentive Plan increasing the number of shares of Common Stock reserved for issuance from 14,230,000 to 20,230,000 and eliminating the limit on the maximum number of shares of Common Stock that may be granted during any calendar year to any one individual;
3.To approve the issuance of equity compensation to the Executive Chairman pursuant to Nasdaq Listing Rule 5635(c) and, if applicable, Nasdaq Listing Rule 5635(b);
4.To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
5.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2017-04-14 |
股东大会：
将于2017-06-08召开股东大会
会议内容 ▼▲
- 1.To elect two directors;
2.To approve the amendment to our 2011 Long-Term Incentive Plan increasing the number of shares of Common Stock reserved for issuance from 11,230,000 to 14,230,000;
3.To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
4.To approve an advisory resolution on executive compensation;
5.To conduct an advisory vote on the frequency of future advisory votes on executive compensation;
6.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2016-04-08 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1. To elect two directors;
2. To approve amendments to our 2011 Long-Term Incentive Plan including the performance goals included therein;
3. To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
4. To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2015-04-17 |
股东大会：
将于2015-06-08召开股东大会
会议内容 ▼▲
- 1.To elect four directors;
2.To approve an amendment to our 2011 Long-Term Incentive Plan increasing the number of shares of Common Stock reserved for issuance from 5,730,000 to 8,230,000;
3.To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2014-10-17 |
股东大会：
将于2014-12-11召开股东大会
会议内容 ▼▲
- 1.To approve the issuance and sale by the Company of shares of the Company’s common stock to Spectrum Pharmaceuticals, Inc. and/or its affiliate, Spectrum Pharmaceuticals Cayman, L.P. (together “Spectrum”) upon the exercise of contingent stock purchase rights that could result in (A) Spectrum owning greater than 20% of the Company’s issued and outstanding shares of common stock after such issuance and require approval under Nasdaq Listing Rule 5635(a) or (B) a change of control of the Company that would require approval under Nasdaq Listing Rule 5635(b).
2.To approve the conversion of all outstanding shares of the Company’s Series A Preferred Stock, if any, issued to Spectrum upon the exercise of the Contingent Purchase Right into shares of the Company’s Common Stock prior to receiving stockholder approval of Proposal 1.
|
| 2014-04-21 |
股东大会：
将于2014-06-12召开股东大会
会议内容 ▼▲
- 1. To elect a director nominee of EntreMed, Inc.;
2. To approve an amendment to the Company’s 2011 Long-Term Incentive Plan increasing (i) the number of shares of Common Stock reserved for issuance from 4,230,000 to 5,730,000;
3. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to change the name of the Company to “CASI Pharmaceuticals, Inc.”;
4. To approve an advisory resolution on executive compensation;
5. To ratify the appointment of CohnReznick LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2014;
6. To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2013-04-16 |
股东大会：
将于2013-05-30召开股东大会
会议内容 ▼▲
- 1. To elect director nominees of EntreMed, Inc.;
2. To approve an amendment to the Company’s 2011 Long-Term Incentive Plan increasing (i) the number of shares of Common Stock reserved for issuance from 1,730,000 to 4,230,000; (ii) the maximum number of shares of Common Stock that may be awarded to any one individual under the Plan from 750,000 to 1,300,000;
3. To ratify the appointment of CohnReznick LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2013;
4. To consider and take action upon such other matters as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|